MedTrace Logo

The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer

NCT03889626 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 242

Last updated 2019-03-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and tolerability of the maintenance treatment of Apatinib/Capecitabine after fluorouracil and platinum based first-line chemotherapy in advanced gastric cancer.

Conditions

  • Stomach Neoplasms
  • Gastrointestinal Neoplasms
  • Stomach Diseases
  • Digestive System Neoplasms
  • Capecitabine
  • Apatinib
  • Neoplasms
  • Molecular Mechanisms of Pharmacological Action

Interventions

DRUG

Apatinib

Apatinib: 500mg qd po, q4w

DRUG

Capecitabine

Capecitabine: 1000mg/m2 bid po, d1-14, q3w

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-22
Primary Completion
2022-03-22
Completion
2024-03-22

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03889626 on ClinicalTrials.gov